Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Irina Dyagil, Hagop M Kantarjian, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD

Blood (2012) 120 (21): 4442.

https://doi.org/10.1182/blood.V120.21.4442.4442

Published: 2012

Journal Articles

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Tim H Brümmendorf, Hagop M. Kantarjian, MD, Carlo Gambacorti-Passerini, Francois Guilhot, Luke Akard, MD, Vaishali Doshi, Jeff H Lipton, MD, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD

Blood (2012) 120 (21): 69.

https://doi.org/10.1182/blood.V120.21.69.69

Published: 2012

Journal Articles

Pharmacokinetics and Tolerability of Bosutinib in Asian Versus Non-Asian Patients with Philadelphia Chromosome–Positive Leukemia

Poe-Hirr Hsyu, Karin Gogat, Ladan Duvillie, Virginia Kelly, Nadine Besson

Blood (2012) 120 (21): 4440.

https://doi.org/10.1182/blood.V120.21.4440.4440

Published: 2012

Journal Articles

Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up

Jorge E Cortes, Anish Maru, Carmino Antonio Antonio De Souza, PhD, François Guilhot, Ladan Duvillie, Christine Powell, Athena Countouriotis, Carlo Gambacorti-Passerini, MD

Blood (2011) 118 (21): 455.

https://doi.org/10.1182/blood.V118.21.455.455

Published: 2011

Journal Articles

The Incidence of Bcr-Abl Mutations and Their Impact on Clinical Outcome in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Bosutinib Versus Imatinib in the BELA Trial

Dong-Wook Kim, Jorge E Cortes, Zvenyslava Maslyak, Raymond Wong, Ladan Duvillie, Christine Powell, Athena Countouriotis, Tim H Brümmendorf

Blood (2011) 118 (21): 2769.

https://doi.org/10.1182/blood.V118.21.2769.2769

Published: 2011

NARROW

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Pharmacokinetics and Tolerability of Bosutinib in Asian Versus Non-Asian Patients with Philadelphia Chromosome–Positive Leukemia

Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up

The Incidence of Bcr-Abl Mutations and Their Impact on Clinical Outcome in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Bosutinib Versus Imatinib in the BELA Trial

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Assessment of Early Molecular Response As a Predictor of Long-Term Clinical Outcomes in the Phase 3 BELA Study

Pharmacokinetics and Tolerability of Bosutinib in Asian Versus Non-Asian Patients with Philadelphia Chromosome–Positive Leukemia

Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up

The Incidence of Bcr-Abl Mutations and Their Impact on Clinical Outcome in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients Treated with Bosutinib Versus Imatinib in the BELA Trial

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only